阿扎胞苷
威尼斯人
相扑蛋白
髓系白血病
癌症研究
髓样
体内
细胞毒性T细胞
白血病
低甲基化剂
免疫学
生物
化学
医学
体外
慢性淋巴细胞白血病
基因
基因表达
泛素
DNA甲基化
生物技术
生物化学
作者
Ludovic Gabellier,Marion de Toledo,Mehuli Chakraborty,Dana Akl,Rawan Hallal,Mays Aqrouq,Giovanni Buonocore,Clara Recasens-Zorzo,Guillaume Cartron,Abigaïl Delort,Marc Piechaczyk,Denis Tempé,Guillaume Bossis
出处
期刊:Haematologica
[Ferrata Storti Foundation]
日期:2023-08-23
卷期号:109 (1): 98-114
被引量:18
标识
DOI:10.3324/haematol.2023.282704
摘要
Acute myeloid leukemias (AML) are severe hematomalignancies with dismal prognosis. The post-translational modification SUMOylation plays key roles in leukemogenesis and AML response to therapies. Here, we show that TAK-981 (subasumstat), a first-in-class SUMOylation inhibitor, is endowed with potent anti-leukemic activity in various preclinical models of AML. TAK-981 targets AML cell lines and patient blast cells in vitro and in vivo in xenografted mice with minimal toxicity on normal hematopoietic cells. Moreover, it synergizes with 5-azacytidine (AZA), a DNA-hypomethylating agent now used in combination with the BCL-2 inhibitor venetoclax to treat AML patients unfit for standard chemotherapies. Interestingly, TAK-981+AZA combination shows higher anti-leukemic activity than AZA+venetoclax combination both in vitro and in vivo, at least in the models tested. Mechanistically, TAK-981 potentiates the transcriptional reprogramming induced by AZA, promoting apoptosis, alteration of the cell cycle and differentiation of the leukemic cells. In addition, TAK-981+AZA treatment induces many genes linked to inflammation and immune response pathways. In particular, this leads to the secretion of type-I interferon by AML cells. Finally, TAK-981+AZA induces the expression of natural killer-activating ligands (MICA/B) and adhesion proteins (ICAM-1) at the surface of AML cells. Consistently, TAK-981+AZA-treated AML cells activate natural killer cells and increase their cytotoxic activity. Targeting SUMOylation with TAK-981 may thus be a promising strategy to both sensitize AML cells to AZA and reduce their immune-escape capacities.
科研通智能强力驱动
Strongly Powered by AbleSci AI